1-3 of 3
Stéphane Champiat
Close
Sort by
Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1040.
https://doi.org/10.1182/blood-2019-124876
Published: 2019
Journal Articles

Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

Jean-Marie Michot, MD, Nicolas Delanoy, Thibault Comont, Nora Kramkimel, Romain Dupont, Julien Lazarovici, MD, Stéphane Champiat, Caroline Robert, Charles Herbaux, MD, Benjamin Besse, Claude Chahine, MD, Aude Guillemin, Christine Mateus, Patricia Pautier, Philippe Saiag, Emmanuela Madonna, Marie Maerevoet, MD, Jean-Christophe Bout, Charlotte Leduc, Pascal Biscay, Gilles Quere, Christophe Nardin, Mikael Ebbo, Laurence Albiges, Grégoire Marret, Virginie Levrat, Cécile Dujon, Salim Laghouati, Laure Croisille, MD PhD, Anne-Laure Voisin, Bertrand Godeau, MD, Christophe Massard, Vincent Ribrag, MD, Aurelien Marabelle, MD PhD, Marc Michel, Olivier Lambotte
Journal: Blood
Blood (2018) 132 (Supplement 1): 2412.
https://doi.org/10.1182/blood-2018-99-110875
Published: 2018
Journal Articles

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Marion Brault, Maxime Annereau, PharmD, Alina Danu, MD, Julien Lazarovici, MD, Claude Chahine, MD, Andrea Varga, Capucine Baldini, Stéphane Champiat, Malik Berhoune, Christophe Massard, François Lemare, Vincent Ribrag, MD, Jean-Marie Michot, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2992.
https://doi.org/10.1182/blood-2018-99-112919
Published: 2018